AstraZeneca COVID-19 vaccine Source: EMA Twitter
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Australia’s medical regulators are urgently reviewing the latest health advice on AstraZeneca’s COVID-19 immunisation
  • The European Medicines Agency (EMA) has confirmed after weeks of investigation that blood clots, while very rare, are a risk for those taking the vaccine
  • But the E.U. medicines watchdog still said the “overall benefits of the vaccine in preventing COVID-19 outweigh the risks of side effects”
  • Australia’s Therapeutic Goods Administration (TGA) and Australian Technical Advisory Group on Immunisation (ATAGI) are now reviewing the EMA’s data
  • Prime Minister Scott Morrison said he expects an update from both agencies by Thursday night before the matter will be discussed in national cabinet
  • The U.K. has already announced plans to offer a different COVID-19 vaccine to those under 30, in the wake of the rare blood clot risk being declared

Australia’s medical regulators are urgently reviewing the latest health advice on AstraZeneca’s COVID-19 immunisation.

The European Medicines Agency (EMA) has confirmed after weeks of investigation that blood clots are a very rare risk for those taking the vaccine.

In a statement, the agency said its safety committee “has concluded today that unusual blood clots with low blood platelets should be listed as very rare side effects.”

The EMA also advised that “the overall benefits of the vaccine in preventing COVID-19 outweigh the risks of side effects.”

Following the European medical watchdog’s announcement, Australia’s Therapeutic Goods Administration (TGA) and Australian Technical Advisory Group on Immunisation (ATAGI) are now reviewing the advice.

Australia’s Prime Minister Scott Morrison said he expects an update from both agencies by Thursday night.

The PM will then discuss the latest information with State and Territory Leaders in Friday’s national cabinet meeting.

Scott Morrison also stated that Australia’s vaccine rollout, which consists primarily of the AstraZeneca jab, will not be changed.

“At this point, there’s no advice to suggest there would be any change to the rollout of the vaccine.”

In the U.K., the government has already begun implementing changes to its vaccine rollout in light of the latest risk update.

The country’s drug regulator also carried out its own, separate review of the AstraZeneca COVID-19 vaccine and found under-30s should be offered a different type of immunisation.

Despite the recommendation though, British Prime Minister Boris Johnson said the AstraZeneca jab was still safe and effective.

The U.K. leader said the vaccine had already saved thousands of lives and will still be used in the country’s vaccination rollout.

More From The Market Online

Well below US$5K/oz, gold’s surefire status as a safe haven has shifted

In the post-COVID-19 world, it’s almost definitely news to nobody reading this that gold prices have staged a fairly historic run.
The Market Online Video

From the Wire: Why did the RBA cut last year just to walk it all back 12 months later?

The Reserve Bank of Australia made the call to hike interest rates again in CY26, using its second board meeting to bring them
ASX concept

ASX 200 reacts to an RBA 25bps rate hike by… closing somewhat firmly in the green?

Colour me surprised – the ASX200 successfully priced something in for once, with today’s RBA rate hike not scaring the market down into
India Russia flag

Not just AUKUS indexes: USA’s war on Iran visible on India’s NIFTY; Russia’s MOEX

While the Australian market is busy watching Wall Street, gold, and oil prices – and the prices of relevant stocks exposed to those